These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24165174)

  • 1. Characterizing in vivo pharmacodynamics of carbapenems against Acinetobacter baumannii in a murine thigh infection model to support breakpoint determinations.
    Macvane SH; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2014; 58(1):599-601. PubMed ID: 24165174
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of Meropenem against Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.
    Sabet M; Tarazi Z; Griffith DC
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988101
    [No Abstract]   [Full Text] [Related]  

  • 4. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.
    Dudhani RV; Turnidge JD; Nation RL; Li J
    J Antimicrob Chemother; 2010 Sep; 65(9):1984-90. PubMed ID: 20573659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.
    Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Shigemi A; Umezaki Y; Nakamura K; Ueno K; Morikawa N; Takeda Y
    Int J Antimicrob Agents; 2014 Jun; 43(6):547-52. PubMed ID: 24796218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model.
    Kang AD; Smith KP; Berg AH; Truelson KA; Eliopoulos GM; McCoy C; Kirby JE
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
    Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
    J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model.
    Zhou J; Ledesma KR; Chang KT; Abodakpi H; Gao S; Tam VH
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections.
    Tal-Jasper R; Katz DE; Amrami N; Ravid D; Avivi D; Zaidenstein R; Lazarovitch T; Dadon M; Kaye KS; Marchaim D
    Antimicrob Agents Chemother; 2016 May; 60(5):3127-31. PubMed ID: 26883694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.
    Bowker KE; Noel AR; Tomaselli SG; Elliott H; Macgowan AP
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5009-15. PubMed ID: 22713338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
    Koomanachai P; Kim A; Nicolau DP
    J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Almarzoky Abuhussain SS; Avery LM; Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.
    Rao GG; Ly NS; Bulitta JB; Soon RL; San Roman MD; Holden PN; Landersdorfer CB; Nation RL; Li J; Forrest A; Tsuji BT
    J Antimicrob Chemother; 2016 Nov; 71(11):3148-3156. PubMed ID: 27494922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.
    Pongpech P; Amornnopparattanakul S; Panapakdee S; Fungwithaya S; Nannha P; Dhiraputra C; Leelarasamee A
    J Med Assoc Thai; 2010 Feb; 93(2):161-71. PubMed ID: 20301995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
    Housman ST; Hagihara M; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.
    Lepak AJ; Trang M; Hammel JP; Sader HS; Bhavnani SM; VanScoy BD; Pogue JM; Ambrose PG; Andes DR;
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0145222. PubMed ID: 36946729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable polymyxin B susceptibility among carbapenem-resistant Acinetobacter baumannii: for how long?
    Reus Rodrigues Perez L; Luís Barth A
    J Chemother; 2017 Feb; 29(1):60-61. PubMed ID: 26300348
    [No Abstract]   [Full Text] [Related]  

  • 18. [In vitro tigecycline and carbapenem susceptibilities of clinical Acinetobacter baumannii isolates].
    Nayman Alpat S; Aybey AD; Akşit F; Ozgüneş I; Kiremitçi A; Usluer G
    Mikrobiyol Bul; 2010 Oct; 44(4):641-5. PubMed ID: 21063976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model.
    Stainton SM; Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30420477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized Exposures of a β-Lactam-β-Lactamase Inhibitor, Tazobactam, versus Non-β-Lactam-β-Lactamase Inhibitor, Avibactam, with or without Colistin, against Acinetobacter baumannii in Murine Thigh and Lung Infection Models.
    Monogue ML; Sakoulas G; Nizet V; Nicolau DP
    Pharmacology; 2018; 101(5-6):255-261. PubMed ID: 29533955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.